FCPR03 - ≥99% , CAS No.1917347-65-9

CAS: 1917347-65-9 Cat. No.: F648779 Peso molecular: 299.31

GRADE & PURITY ≥99%

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Descripción general

FCPR03 is a potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC 50 values of 60 nM, 31 nM and 47 nM for PDE4 catalytic domain , PDE4B1 and PDE4D7 , respectively. FCPR03 displays at least 2100-fold selectivity over other PDEs (PDE1-3 and PDE5-11). FCPR03 has anti-inflammatory, neuroprotective and antidepressant-like effects

In Vitro

FCPR03 (5-20 μM; 30 hours; HT-22 cells) treatment increases cell viability (oxygen-glucose deprivation (OGD)-induced) in a dose-dependent manner, and 10 μM FCPR03 shows significant protective effects. FCPR03 (20 μM; 30 hours; HT-22 cells) treatment protects against OGD-induced cellular apoptosis in both HT-22 cells and cortical neurons. The levels of mitochondrial membrane potential (MMP) and ROS are also restored by FCPR03. FCPR03 (20 μM; 30 hours; HT-22 cells) treatment increases the levels of phosphorylated AKT, glycogen synthase kinase-3β (GSK3β), and β-catenin. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HT-22 cells Concentration: 5 μM, 10 μM, 20 μM Incubation Time: 30 hours Result: Increased cell viability in a dose-dependent manner. Apoptosis AnalysisCell Line: HT-22 cells Concentration: 20 μM Incubation Time: 30 hours Result: Reversed the effects of OGD and decreased the ratio of apoptotic cells. Western Blot AnalysisCell Line: HT-22 cells Concentration: 20 μM Incubation Time: 30 hours Result: Increased the levels of phosphorylated AKT, glycogen synthase kinase-3β (GSK3β), and β-catenin.

In Vivo

FCPR03 (1.25-5 mg/kg; intraperitoneal injection; once; adult male Sprague-Dawley rats) treatment reduces the infarct volume and improves neurobehavioral outcomes in rats following MCAO. FCPR03 increases the levels of phosphorylated AKT, GSK3β and β-catenin within the ischemic penumbra of rats following cerebral ischemia-reperfusion . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Adult male Sprague-Dawley rats (250-280 g) induced middle cerebral artery occlusion (MCAO) Dosage: 1.25 mg/kg, 2.5 mg/kg, 5 mg/kg Administration: Intraperitoneal injection; once Result: Reduced the infarct volume and improved neurobehavioral outcomes in rats following MCAO.

Form:Solid

IC50& Target:PDE4 catalytic domain 60 nM (IC 50 ) PDE4B1 31 nM (IC 50 ) PDE4D7 47 nM (IC 50 )

Specifications

Especificaciones y pureza

≥99%

Mecanismos bioquímicos y fisiológicos

FCPR03 is a potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC 50 values of 60 nM, 31 nM and 47 nM for PDE4 catalytic domain , PDE4B1 and PDE4D7 , respectively. FCPR03 displays at least 2100-fold selectivity over other PDEs (PDE1-3 and PDE5

Condiciones de almacenamiento de almacenamiento

Store at -20°C

Enviado en

Ice chest + Ice pads

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Tipo de acción

INHIBITOR

Pureza

≥99%

Nombres e identificadores

• Peso molecular: 299.31

Propiedades químicas y físicas

• Solubilidad: DMSO : 100 mg/mL (334.10 mM; Need ultrasonic)